Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
302.00K | 314.00K | 1.77M | 2.96M | 1.05M | Gross Profit |
302.00K | -1.01M | 1.02M | 2.34M | -27.25M | EBIT |
-299.04M | -254.45M | -134.30M | -79.73M | -110.38M | EBITDA |
-266.36M | -234.56M | -128.63M | -78.79M | -109.67M | Net Income Common Stockholders |
-269.95M | -237.73M | -125.44M | -79.42M | -110.98M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
717.58M | 477.37M | 424.55M | 196.97M | 127.64M | Total Assets |
742.40M | 490.42M | 435.09M | 203.71M | 131.25M | Total Debt |
21.09M | 21.05M | 5.26M | 520.00K | 455.00K | Net Debt |
-78.50M | -81.78M | -150.32M | -41.78M | -45.44M | Total Liabilities |
70.76M | 48.40M | 40.03M | 15.99M | 11.22M | Stockholders Equity |
671.64M | 442.02M | 395.06M | 187.72M | 120.04M |
Cash Flow | Free Cash Flow | |||
-232.83M | -185.07M | -94.64M | -54.92M | -29.82M | Operating Cash Flow |
-232.32M | -184.17M | -93.84M | -54.58M | -29.78M | Investing Cash Flow |
-228.65M | -94.25M | -115.13M | -74.29M | -50.48M | Financing Cash Flow |
457.74M | 225.67M | 322.24M | 125.28M | 101.31M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
69 Neutral | $1.13B | 213.47 | 1.52% | ― | 33.97% | ― | |
52 Neutral | $5.28B | 3.75 | -42.72% | 2.86% | 17.70% | 2.03% | |
51 Neutral | $1.19B | ― | -73.24% | ― | -4.42% | -42.17% | |
48 Neutral | $1.11B | ― | -57.48% | ― | 13698.99% | 31.46% | |
48 Neutral | $1.19B | ― | -75.69% | ― | ― | -25.83% | |
43 Neutral | $910.79M | ― | -66.09% | ― | 32387.34% | 15.93% | |
41 Neutral | $1.11B | ― | -45.77% | ― | -3.82% | 29.10% |
On April 7, 2025, Viridian Therapeutics announced the appointment of Jeff Ajer to its Board of Directors. Mr. Ajer brings over 25 years of experience in commercialization for rare diseases, having previously served as Chief Commercial Officer at BioMarin Pharmaceutical. His expertise is expected to bolster Viridian’s commercial strategy as the company advances its pipeline, including veligrotug for thyroid eye disease. Additionally, Viridian announced inducement grants of stock options to new employees, aligning with its growth and recruitment strategies.
Spark’s Take on VRDN Stock
According to Spark, TipRanks’ AI Analyst, (VRDN) is a Neutral.
Viridian Therapeutics’ stock score reflects significant financial challenges and poor technical indicators, offset by positive corporate developments. The absence of revenue and negative cash flows highlight major risks, while the promising clinical trial results offer potential upside. Overall, the stock faces substantial hurdles but has opportunities if it can capitalize on its recent clinical success.
To see Spark’s full report on (VRDN) stock, click here.
On March 3, 2025, Viridian Therapeutics entered into a new Open Market Sale Agreement with Jefferies LLC, allowing the company to offer and sell up to $300 million in common stock to support clinical development and commercialization efforts. This new agreement replaces a prior sale agreement from September 2022, which was terminated after selling $115.2 million in stock, with no costs associated with its early termination.